A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)
Condition: Chronic Hepatitis B Interventions: Drug: HRS9950 tablets; Drug: HRS9950 placebo tablets Sponsor: Chengdu Suncadia Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
Hydroxynidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
Condition: Liver Fibrosis Interventions: Drug: Hydronidone capsules; Drug: The placebo capsules Sponsor: Beijing Continent Pharmaceutical Co, Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy in Combination With NUC for Chronic Hepatitis B
Condition: Chronic Hepatitis B Intervention: Biological: TCR-T Sponsor: Beijing 302 Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)
Condition: Chronic Hepatitis B Interventions: Drug: HRS9950 tablets; Drug: HRS9950 placebo tablets Sponsor: Chengdu Suncadia Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
Hydroxynidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
Condition: Liver Fibrosis Interventions: Drug: Hydronidone capsules; Drug: The placebo capsules Sponsor: Beijing Continent Pharmaceutical Co, Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy in Combination With NUC for Chronic Hepatitis B
Condition: Chronic Hepatitis B Intervention: Biological: TCR-T Sponsor: Beijing 302 Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)
Condition: Chronic Hepatitis B Interventions: Drug: HRS9950 tablets; Drug: HRS9950 placebo tablets Sponsor: Chengdu Suncadia Medicine Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
Hydroxynidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
Condition: Liver Fibrosis Interventions: Drug: Hydronidone capsules; Drug: The placebo capsules Sponsor: Beijing Continent Pharmaceutical Co, Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 15, 2023 Category: Research Source Type: clinical trials
Efficacy and Safety of Hepatitis B Virus Vaccine(HBV) in Treatment of Cutaneous Warts
Condition: Cutaneous Warts Intervention: Drug: Hepatitis B Virus Vaccine(HBV) Sponsor: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 14, 2023 Category: Research Source Type: clinical trials
Effect of aerobic exercise training on the fat fraction of the liver in persons with chronic hepatitis B and hepatic steatosis: Trial protocol for a randomized controlled intervention trial — The FitLiver study
DiscussionThis trial, investigating high-intensity interval training in persons with chronic hepatitis B and hepatic steatosis, is the first exercise intervention trial performed on this group of patients. If exercise reduces hepatic steatosis and induces other beneficial effects of clinical markers in this group of patients, there might be an indication to recommend exercise as part of treatment. Furthermore, the investigation of the effect of exercise on hepatokine secretion will provide more knowledge on the effects of exercise on the liver.Trial registrationDanish Capital Regions committee on health research ethics ref...
Source: Trials - June 13, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
Condition: Hepatocellular Carcinoma Intervention: Drug: Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle Sponsor: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 9, 2023 Category: Research Source Type: clinical trials
